The American Society for Transplantation and Cellular Therapy (ASTCT) published its first white paper on indications for autologous and allogeneic hematopoietic cell transplantation (HCT) in 2015. It was identified at the time that periodic updates of indications would be required to stay abreast with state of the art and emerging indications and therapy. In recent years the field has not only seen an improvement in transplantation technology, thus widening the therapeutic scope of HCT, but additionally a whole new treatment strategy using modified immune effector cells, including chimeric antigen receptor T cells and engineered T-cell receptors, has emerged. The guidelines review committee of the ASTCT deemed it optimal to update the ASTCT recommendations for indications for HCT to include new data and to incorporate indications for immune effector cell therapy (IECT) where appropriate. The guidelines committee established a multiple stakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to provide guidance on indications for HCT and IECT. This article presents the updated recommendations from the ASTCT on indications for HCT and IECT. Indications for HCT/IECT were categorized as (1) Standard of care, where indication is well defined and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but have been shown to be effective therapy; (3) Standard of care, rare indication, for rare diseases where demonstrated effectiveness exists but large clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical and/or early-phase clinical studies show HCT/IECT to be a promising treatment option; and (5) Not generally recommended, where available evidence does not support the routine use of HCT/IECT. The ASTCT will continue to periodically review these guidelines and update them as new evidence becomes available.
Bibliographical noteFunding Information:
Financial disclosure: The authors have nothing to disclose. Conflict of interest statement: N.M.: Consulting: Anthem Inc.; Advisory board: NKarta, Incyte; Honorarium: Malinckrodt. D.M.: Consultancy: Pfizer, Amgen, Novartis. M.H.: Research support/funding: Takeda Pharmaceutical Company, Spectrum Pharmaceuticals, Astellas Pharma; Consultancy: Incyte Corporation, ADC Therapeutics, Celgene Corporation, Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio; Speaker's Bureau: Sanofi Genzyme, AstraZeneca. Financial disclosure: See Acknowledgments on page1254.
© 2020 American Society for Transplantation and Cellular Therapy
- Allogeneic transplantation
- Autologous transplantation
- Chimeric antigen receptor T cells
- Hematopoietic cell transplantation
- Immune effector cell therapy